Interestingly, increased FOXO3 activation in cisplatin resistant colon cancer cells with a small molecule inhibitor, tricirbine/API-2, can reverse cisplatin resistance by blocking Akt [26]. Here, AKT1 is linked to malignant colon neoplasm.